Skip to main content
Top
Published in: BMC Neurology 1/2014

Open Access 01-12-2014 | Research article

Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study

Authors: Shu-yang Yu, Li-jun Zuo, Fang Wang, Ze-jie Chen, Yang Hu, Ya-jie Wang, Xiao-min Wang, Wei Zhang

Published in: BMC Neurology | Issue 1/2014

Login to get access

Abstract

Background

Cognitive impairment strikingly reduces the quality of life of Parkinson’s disease (PD) patients. Studies find that pathological proteins, neuroinflammatory factors and free radicals may involve in the pathogenesis of cognitive impairment of PD, however, results are inconclusive.

Methods

We recruited 62 PD patients and 31 healthy controls. PD patients were identified with cognitive impairment, including PD with mild cognitive impairment (PD-MCI) and PD with dementia (PDD) according to the diagnostic criteria for PD-MCI and PDD issued by Movement Disorder Society Task Force. The levels of pathological proteins, including β-amyloid 1–42 (Aβ1-42),Total-tau (T-tau) and phosphorelated tau (P-tau), neuroinflammatory factors,including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interferon-γ (INF-γ) and prostaglandin E2 (PGE2), free radicals, including hydroxyl radical (·OH), hydrogen peroxide (H2O2) and nitric oxide (NO) in cerebrospinal fluid(CSF) were detected. The levels of above factors in CSF were compared among healthy controls and patients with and without cognitive impairment. Correlation analyses were performed between Montreal Cognitive Assessment (MoCA) score and the levels of above factors in CSF.

Results

T-tau level in CSF from PD-CI patients are significantly elevated comparing with those without cognitive impairment and controls (P = 0.016 and 0.004, respectively). The levels of P-tau (S396) and · OH in PD-CI patients are significantly higher than controls (P = 0.001 and 0.014, respectively). IL-6 levels in PD-CI patients are strikingly enhanced comparing with those without cognitive impairment (P = 0.005). MoCA score is negatively correlated with the levels of T-tau (r = -0.340), P-tau (S396) (r = -0.448), IL-6 (r = -0.489) and · OH (r = -0.504) in PD-CI patients.

Conclusions

Elevated levels of T-tau, P-tau (S396), IL-6 and · OH in CSF are significantly correlated with cognitive impairment in PD patients. This investigation may suggest the potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment.
Literature
1.
go back to reference Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M: Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010, 75: 1062-1069. 10.1212/WNL.0b013e3181f39d0e.CrossRefPubMedPubMedCentral Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M: Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010, 75: 1062-1069. 10.1212/WNL.0b013e3181f39d0e.CrossRefPubMedPubMedCentral
2.
go back to reference Petersen RC, Morris JC: Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol. 2005, 62: 1160-1163. 10.1001/archneur.62.7.1160. discussion 1167CrossRefPubMed Petersen RC, Morris JC: Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol. 2005, 62: 1160-1163. 10.1001/archneur.62.7.1160. discussion 1167CrossRefPubMed
3.
go back to reference Halliday GM, McCann H: The progression of pathology in Parkinson’s disease. Ann N Y Acad Sci. 2010, 1184: 188-195. 10.1111/j.1749-6632.2009.05118.x.CrossRefPubMed Halliday GM, McCann H: The progression of pathology in Parkinson’s disease. Ann N Y Acad Sci. 2010, 1184: 188-195. 10.1111/j.1749-6632.2009.05118.x.CrossRefPubMed
4.
go back to reference Block ML, Hong JS: Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005, 76: 77-98. 10.1016/j.pneurobio.2005.06.004.CrossRefPubMed Block ML, Hong JS: Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005, 76: 77-98. 10.1016/j.pneurobio.2005.06.004.CrossRefPubMed
5.
go back to reference Zhang W, Phillips K, Wielgus AR, Liu J, Albertini A, Zucca FA, Faust R, Qian SY, Miller DS, Chignell CF, Wilson B, Jackson-Lewis V, Przedborski S, Joset D, Loike J, Hong JS, Sulzer D, Zecca L: Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson’s disease. Neurotox Res. 2011, 19: 63-72. 10.1007/s12640-009-9140-z.CrossRefPubMed Zhang W, Phillips K, Wielgus AR, Liu J, Albertini A, Zucca FA, Faust R, Qian SY, Miller DS, Chignell CF, Wilson B, Jackson-Lewis V, Przedborski S, Joset D, Loike J, Hong JS, Sulzer D, Zecca L: Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson’s disease. Neurotox Res. 2011, 19: 63-72. 10.1007/s12640-009-9140-z.CrossRefPubMed
6.
go back to reference Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O: Cerebrospinal fluid inflammatory markers in Parkinson’s disease–associations with depression, fatigue, and cognitive impairment. Brain Behav Immun. 2013, 33: 183-189.CrossRefPubMed Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O: Cerebrospinal fluid inflammatory markers in Parkinson’s disease–associations with depression, fatigue, and cognitive impairment. Brain Behav Immun. 2013, 33: 183-189.CrossRefPubMed
7.
go back to reference Hritcu L, Ciobica A, Stefan M, Mihasan M, Palamiuc L, Nabeshima T: Spatial memory deficits and oxidative stress damage following exposure to lipopolysaccharide in a rodent model of Parkinson’s disease. Neurosci Res. 2011, 71: 35-43. 10.1016/j.neures.2011.05.016.CrossRefPubMed Hritcu L, Ciobica A, Stefan M, Mihasan M, Palamiuc L, Nabeshima T: Spatial memory deficits and oxidative stress damage following exposure to lipopolysaccharide in a rodent model of Parkinson’s disease. Neurosci Res. 2011, 71: 35-43. 10.1016/j.neures.2011.05.016.CrossRefPubMed
8.
go back to reference Kaur H, Chauhan S, Sandhir R: Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson’s disease. Neurochem Res. 2011, 36: 1435-1443. 10.1007/s11064-011-0469-3.CrossRefPubMed Kaur H, Chauhan S, Sandhir R: Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson’s disease. Neurochem Res. 2011, 36: 1435-1443. 10.1007/s11064-011-0469-3.CrossRefPubMed
9.
go back to reference Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992, 55: 181-184. 10.1136/jnnp.55.3.181.CrossRefPubMedPubMedCentral Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992, 55: 181-184. 10.1136/jnnp.55.3.181.CrossRefPubMedPubMedCentral
10.
go back to reference Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M: Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012, 27: 349-356. 10.1002/mds.24893.CrossRefPubMedPubMedCentral Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M: Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012, 27: 349-356. 10.1002/mds.24893.CrossRefPubMedPubMedCentral
11.
go back to reference Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M: Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007, 22: 2314-2324. 10.1002/mds.21844.CrossRefPubMed Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M: Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007, 22: 2314-2324. 10.1002/mds.21844.CrossRefPubMed
12.
go back to reference Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA: Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain. 2007, 130: 1787-1798. 10.1093/brain/awm111.CrossRefPubMed Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA: Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain. 2007, 130: 1787-1798. 10.1093/brain/awm111.CrossRefPubMed
13.
go back to reference Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, Marti MJ, Valldeoriola F, Bargallo N, Junque C: Hippocampal head atrophy predominance in Parkinson’s disease with hallucinations and with dementia. J Neurol. 2008, 255: 1324-1331. 10.1007/s00415-008-0885-8.CrossRefPubMed Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, Marti MJ, Valldeoriola F, Bargallo N, Junque C: Hippocampal head atrophy predominance in Parkinson’s disease with hallucinations and with dementia. J Neurol. 2008, 255: 1324-1331. 10.1007/s00415-008-0885-8.CrossRefPubMed
14.
go back to reference Kehagia AA, Barker RA, Robbins TW: Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010, 9: 1200-1213. 10.1016/S1474-4422(10)70212-X.CrossRefPubMed Kehagia AA, Barker RA, Robbins TW: Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010, 9: 1200-1213. 10.1016/S1474-4422(10)70212-X.CrossRefPubMed
15.
go back to reference Bondi MW, Kaszniak A, Bayles KA, Vance KT: Contributions of frontal system dysfunction to memory and perceptual abilities in parkinson’s disease. Neuropsychology. 1993, 7: 14-CrossRef Bondi MW, Kaszniak A, Bayles KA, Vance KT: Contributions of frontal system dysfunction to memory and perceptual abilities in parkinson’s disease. Neuropsychology. 1993, 7: 14-CrossRef
16.
go back to reference Cronin-Golomb A, Braun AE: Visuospatial dysfunction and problem solving in Parkinson’s disease. Neuropsychology. 1997, 11: 44-52.CrossRefPubMed Cronin-Golomb A, Braun AE: Visuospatial dysfunction and problem solving in Parkinson’s disease. Neuropsychology. 1997, 11: 44-52.CrossRefPubMed
17.
go back to reference Crucian GP, Okun MS: Visual-spatial ability in Parkinson’s disease. Front Biosci. 2003, 8: s992-s997. 10.2741/1171.CrossRefPubMed Crucian GP, Okun MS: Visual-spatial ability in Parkinson’s disease. Front Biosci. 2003, 8: s992-s997. 10.2741/1171.CrossRefPubMed
18.
go back to reference Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, Barker RA: The natural history of treated Parkinson’s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry. 2011, 82: 1112-1118. 10.1136/jnnp.2011.240366.CrossRefPubMed Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, Barker RA: The natural history of treated Parkinson’s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry. 2011, 82: 1112-1118. 10.1136/jnnp.2011.240366.CrossRefPubMed
19.
go back to reference Armstrong MJ, Naglie G, Duff-Canning S, Meaney C, Gill D, Eslinger PJ, Zadikoff C, Mapstone M, Chou KL, Persad C, Litvan I, Mast BT, Fox S, Tang-Wai DF, Marras C: Roles of education and IQ in cognitive reserve in Parkinson’s disease-mild cognitive impairment. Dement Geriatr Cogn Disord Extra. 2012, 2: 343-352. 10.1159/000341782.CrossRef Armstrong MJ, Naglie G, Duff-Canning S, Meaney C, Gill D, Eslinger PJ, Zadikoff C, Mapstone M, Chou KL, Persad C, Litvan I, Mast BT, Fox S, Tang-Wai DF, Marras C: Roles of education and IQ in cognitive reserve in Parkinson’s disease-mild cognitive impairment. Dement Geriatr Cogn Disord Extra. 2012, 2: 343-352. 10.1159/000341782.CrossRef
20.
go back to reference Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C: CSF amyloid {beta} 1–42 predicts cognitive decline in Parkinson disease. Neurology. 2010, 75: 1055-1061. 10.1212/WNL.0b013e3181f39a78.CrossRefPubMedPubMedCentral Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C: CSF amyloid {beta} 1–42 predicts cognitive decline in Parkinson disease. Neurology. 2010, 75: 1055-1061. 10.1212/WNL.0b013e3181f39a78.CrossRefPubMedPubMedCentral
21.
go back to reference Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J: CSF Abeta(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord. 2010, 25: 2682-2685. 10.1002/mds.23287.CrossRefPubMedPubMedCentral Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J: CSF Abeta(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord. 2010, 25: 2682-2685. 10.1002/mds.23287.CrossRefPubMedPubMedCentral
22.
go back to reference Jellinger K: Heterogenous mechanisms of mild cognitive impairment in Parkinson’s disease. J Neural Transm. 2012, 119: 2- Jellinger K: Heterogenous mechanisms of mild cognitive impairment in Parkinson’s disease. J Neural Transm. 2012, 119: 2-
23.
go back to reference Hirsch EC, Hunot S: Neuroinflammation in Parkinson’s disease: a target for neuroprotection?. Lancet Neurol. 2009, 8: 382-397. 10.1016/S1474-4422(09)70062-6.CrossRefPubMed Hirsch EC, Hunot S: Neuroinflammation in Parkinson’s disease: a target for neuroprotection?. Lancet Neurol. 2009, 8: 382-397. 10.1016/S1474-4422(09)70062-6.CrossRefPubMed
24.
go back to reference Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T: Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994, 165: 208-210. 10.1016/0304-3940(94)90746-3.CrossRefPubMed Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T: Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994, 165: 208-210. 10.1016/0304-3940(94)90746-3.CrossRefPubMed
25.
go back to reference Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P: Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett. 1995, 202: 17-20. 10.1016/0304-3940(95)12192-7.CrossRefPubMed Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P: Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett. 1995, 202: 17-20. 10.1016/0304-3940(95)12192-7.CrossRefPubMed
26.
go back to reference Muller T, Blum-Degen D, Przuntek H, Kuhn W: Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson’s disease. Acta Neurol Scand. 1998, 98: 142-144.CrossRefPubMed Muller T, Blum-Degen D, Przuntek H, Kuhn W: Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson’s disease. Acta Neurol Scand. 1998, 98: 142-144.CrossRefPubMed
27.
go back to reference Barnum CJ, Tansey MG: Modeling neuroinflammatory pathogenesis of Parkinson’s disease. Prog Brain Res. 2010, 184: 113-132.CrossRefPubMed Barnum CJ, Tansey MG: Modeling neuroinflammatory pathogenesis of Parkinson’s disease. Prog Brain Res. 2010, 184: 113-132.CrossRefPubMed
28.
go back to reference Jefferson AL, Massaro JM, Beiser AS, Seshadri S, Larson MG, Wolf PA, Au R, Benjamin EJ: Inflammatory markers and neuropsychological functioning: the Framingham Heart Study. Neuroepidemiology. 2011, 37: 21-30. 10.1159/000328864.CrossRefPubMedPubMedCentral Jefferson AL, Massaro JM, Beiser AS, Seshadri S, Larson MG, Wolf PA, Au R, Benjamin EJ: Inflammatory markers and neuropsychological functioning: the Framingham Heart Study. Neuroepidemiology. 2011, 37: 21-30. 10.1159/000328864.CrossRefPubMedPubMedCentral
29.
go back to reference Kamer AR, Morse DE, Holm-Pedersen P, Mortensen EL, Avlund K: Periodontal inflammation in relation to cognitive function in an older adult Danish population. J Alzheimers Dis. 2012, 28: 613-624.PubMed Kamer AR, Morse DE, Holm-Pedersen P, Mortensen EL, Avlund K: Periodontal inflammation in relation to cognitive function in an older adult Danish population. J Alzheimers Dis. 2012, 28: 613-624.PubMed
30.
go back to reference Fragiadaki K, Tektonidou MG, Konsta M, Chrousos GP, Sfikakis PP: Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J Rheumatol. 2012, 39: 60-62. 10.3899/jrheum.110617.CrossRefPubMed Fragiadaki K, Tektonidou MG, Konsta M, Chrousos GP, Sfikakis PP: Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J Rheumatol. 2012, 39: 60-62. 10.3899/jrheum.110617.CrossRefPubMed
31.
go back to reference Cibelli M, Fidalgo AR, Terrando N, Ma D, Monaco C, Feldmann M, Takata M, Lever IJ, Nanchahal J, Fanselow MS, Maze M: Role of interleukin-1beta in postoperative cognitive dysfunction. Ann Neurol. 2010, 68: 360-368. 10.1002/ana.22082.CrossRefPubMedPubMedCentral Cibelli M, Fidalgo AR, Terrando N, Ma D, Monaco C, Feldmann M, Takata M, Lever IJ, Nanchahal J, Fanselow MS, Maze M: Role of interleukin-1beta in postoperative cognitive dysfunction. Ann Neurol. 2010, 68: 360-368. 10.1002/ana.22082.CrossRefPubMedPubMedCentral
32.
go back to reference Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ: In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006, 21: 404-412. 10.1016/j.nbd.2005.08.002.CrossRefPubMed Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ: In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006, 21: 404-412. 10.1016/j.nbd.2005.08.002.CrossRefPubMed
33.
go back to reference Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O: Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment. Brain Behav Immun. 2013, 13: 7- Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O: Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment. Brain Behav Immun. 2013, 13: 7-
34.
go back to reference Gironi M, Bianchi A, Russo A, Alberoni M, Ceresa L, Angelini A, Cursano C, Mariani E, Nemni R, Kullmann C, Farina E, Martinelli Boneschi F: Oxidative imbalance in different neurodegenerative diseases with memory impairment. Neurodegener Dis. 2011, 8: 129-137. 10.1159/000319452.CrossRefPubMed Gironi M, Bianchi A, Russo A, Alberoni M, Ceresa L, Angelini A, Cursano C, Mariani E, Nemni R, Kullmann C, Farina E, Martinelli Boneschi F: Oxidative imbalance in different neurodegenerative diseases with memory impairment. Neurodegener Dis. 2011, 8: 129-137. 10.1159/000319452.CrossRefPubMed
Metadata
Title
Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study
Authors
Shu-yang Yu
Li-jun Zuo
Fang Wang
Ze-jie Chen
Yang Hu
Ya-jie Wang
Xiao-min Wang
Wei Zhang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2014
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-14-113

Other articles of this Issue 1/2014

BMC Neurology 1/2014 Go to the issue